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Abstract: The extracellular aggregation of insoluble protein deposits of amyloid-β 
(Aβ) into plaques and the hyperphosphorylation of the intracellular protein tau 
leading to neurofibrillary tangles are the main pathological hallmarks of 
Alzheimer’s disease  (AD). Both Aβ and tau are metal-binding  proteins. Essential 
trace metals such as zinc, copper, and iron play important roles in healthy brain 
function but altered homeostasis and distribution have been linked to neurode-
generative diseases and  aging. In addition, the presence of non-essential trace 
metals such as aluminum has been associated with  AD. Trace metals and abnor-
mal metal metabolism can influence protein aggregation, synaptic signaling path-
ways, mitochondrial function, oxidative stress levels, and inflammation, ultimately 
resulting in synapse dysfunction and neuronal loss in the AD  brain. Herein we 
provide an overview of metals and metal-binding proteins and their pathophysi-
ological role in  AD.
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INTRODUCTION
Essential trace metals and those with biological functions (biometals) play a vital 
role in many physiological processes in the human  body. As free ion, some of 
them can participate in cellular signaling pathways, while bound to proteins 
they may have a structural or regulatory role in protein folding and  function. 
The fact that about 10% of the genes in the human genome encode for proteins 
with zinc (Zn)-binding motif points to the evident dependency of biological 
processes on this trace  metal. This number of Zn-binding proteins is not even 
accounting for Zn coordinated between two proteins in protein–protein interac-
tions (1). In addition to Zn, several proteins and processes depend on other 
essential trace metals, the most important of which are iron (Fe), manganese 
(Mn), copper (Cu), and selenium (Se) (a  metalloid). The average human body 
contains about 4.2 g Fe, 2.3 g Zn, 0.072 g Cu, 0.015 g Se, and 0.012 g Mn (2). 
However, the distribution of trace metals can vary depending on the organ 
 considered. In the human brain, Fe is the most prevalent trace metal, which can 
be found both as heme (bound to hemoglobin in blood) and non-heme  Fe. Heme-
bound Fe may be a major contributor to the overall  concentration. Therefore, 
Zn, the second most prevalent metal, may play an even more prominent role in 
the brain, which is underlined by its function as neurotransmitter/neuromodula-
tor (3). Additionally, within the brain, some trace metals are enriched in particu-
lar brain regions (Figure 1). For example, the hippocampus is a brain region that 
is high in Zn, while the nucleus caudatus has higher levels of Fe than several 
other brain regions (4, 5). This unequal concentration of trace elements in dif-
ferent tissues demands a tightly regulated  distribution. Given that charged mol-
ecules such as metal ions cannot freely pass the cellular membrane, a plethora of 
transport proteins evolved, with very specific regional and also developmentally 
and environmentally dependent  expression. Especially, the regulation of metal 
concentrations in the brain faces a tight control at the level of the blood–brain 
barrier (BBB), a barrier composed of endothelial cells of the brain capillaries, 
pericytes, astrocytes, and the basement membrane (6). Together, they form a 
functional unit, mediating the exchange of trace metals between neurons, capil-
laries, and glia, while protecting against neurotoxicity of non-essential trace 
 metals or excessive levels of essential trace  elements. A specific set of transport-
ers allows the crossing of trace metals into the  brain. For example, only for Zn, 
24 different transport proteins are known in humans (7), which allow the estab-
lishment of zinc homeostasis in  tissues.
The maintenance of a balance between biometals is complicated by the influ-
ence different metals have on each  other. Their concentration is regulated by 
complex interactions between trace metal ions and their  ligands. For example, 
due to their physicochemical nature, Zn and Cu are known to compete for the 
binding sites of some transporters and metal-binding proteins, resulting in an 
antagonistic relationship, where low levels of Zn increase Cu levels and vice 
versa (8). Due to these interactions, the loss of, or increase in, one trace metal can 
lead to the establishment of a completely new biometal profile affecting many 
other trace metals of a system (9).
Metal homeostasis can be challenged in many  ways. In fact, our body is not 
only exposed to essential trace  metals. Through the environment  (e.g., air, food, 
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medical devices, and cosmetic products), other nonessential trace elements 
such as lead (Pb), mercury (Hg), and aluminum (Al) may enter our  system. 
Indeed, these metals are present in all humans at low levels  (e.g., 0.060 g Al, 
0.012 g Pb, and 0.006 g  Hg). Some of these metals are currently reported to 
have no or little effect on the body  [e.g., titanium (Ti)], while others can pro-
duce adverse effects even at concentrations slightly above the normal back-
ground levels  [e.g., Pb, Hg, and cadmium  (Cd)]. These toxic effects are usually 
due to a chemical nature similar to that of an essential metal that allows binding 
to metal-binding sites of metal transporters and other proteins, leading to com-
petition with essential trace  metals. However, toxic metals are often not able to 
produce the biological effect of essential metals, and therefore, they act 
 antagonistically. Recent  evidences put synaptic signaling, synapse formation and 
Figure 1 Trace metal concentration in different brain regions.  Within the brain, trace metals 
are unequally concentrated in different brain regions. The figure shows the concentrations 
in µg/g brain tissue in the human cortex, hippocampus, thalamus, and caudate nucleus for 
Fe, Zn, Cu, Mn, and Se. This metal homeostasis can be challenged by environmental factors, 
the presence of pathologies such as aggregates of metal-binding proteins, and aging.
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plasticity, oxidative stress, inflammation, and protein aggregation at the fore-
front of disease-relevant processes caused by abnormal trace metal homeostasis 
(Figure 1).
The enrichment of biometals in a tissue may occur through several mecha-
nisms, such as mutations in metal import and export proteins, proteins buffering 
metals through transient binding  (e.g. metallothioneins) (10), and also the abnor-
mal accumulation of metal-binding proteins that occurs in several neurodegenera-
tive diseases such as Parkinson’s disease (alpha-synuclein protein) (11) and 
Alzheimer’s disease  (AD).
In AD, a contribution of abnormal trace metal homeostasis and signaling has 
been extensively reported (9). However, changes in trace metals’ levels in AD are 
complex and can rarely be directly associated with systemic alterations that can 
be measured in easily accessible biosamples such as  serum. The most likely rea-
son for this is the ability of senile plaques to sequester specific metal ions that in 
turn become mislocalized instead of decreasing or increasing  systemically. Cu, 
Zn, and, to a lesser extent, Fe are known to associate with senile plaques made 
of beta-amyloid (Aβ) protein (see  below). It is hypothesized that this association 
causes several biological  effects. For example, sequestration of Cu and Zn into 
plaques leads to an abnormal distribution of these metals, initially resulting in a 
deficiency of Cu and Zn in the vicinity of plaques (12, 13) and not throughout 
the whole  brain.
Therefore, findings concerning alterations in metal ions in AD are highly 
dependent on the tissue and resolution used for  analysis. Regarding essential 
 metals, although results vary in some studies, Mn, Cu, Fe, and Zn seem to show 
an inverse correlation with senile plaque load and thus a decrease in the cerebro-
spinal fluid (CSF) (14) of AD  patients.
The accumulation of trace elements, including Al, Pb, Hg, Cu, and Fe, has 
been implicated in AD through an increase in oxidative stress (15). In particular, 
a disruption in the homeostasis of Cu and Fe, two redox-active metals, may 
increase lipid peroxidation, and the oxidative damage to neurofibrillary tangles 
(NFTs), senile plaques, and nucleic acids (16). Oxidative stress is induced by an 
imbalance in the redox state, involving the generation of excessive reactive oxygen 
species (ROS) or the dysfunction of the antioxidant system (17). Cu is a potent 
mediator of the highly reactive hydroxyl radical (OH•) and is highly concentrated 
in senile  plaques. Consequently, Cu contributes to the increase of oxidative stress 
in  AD. In addition, increased levels of Fe, transferrin, and ferritin may contribute 
to NFT formation, possibly due to the binding of Fe to the tau  protein. In the 
brain, oxidative stress may cause serious damage via several mechanisms, includ-
ing the release of excitatory amino acids and neurotoxicity (18). Although Zn is 
redox-inert, Zn signaling plays a role in the regulation of proteins  (e.g., enzymes 
kinases and phosphatases) controlling redox-signaling  pathways. Therefore, while 
not acting as an electron donor, Zn plays a role in redox biology, where zinc, in 
general, is considered as an  antioxidant. However, these indirect antioxidant-like 
effects are present only in certain conditions and both a lack and excess of Zn can 
result in pro-oxidant effects (19).
In addition to changes in trace metal homeostasis resulting from AD, it is 
likely that alterations may also facilitate and trigger the development of AD 
 pathology. For example, it has been shown that the levels of Zn decrease during 
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aging as a result of more restricted food choice (20, 21), which may facilitate 
inflammatory processes (22), increase oxidative stress (19), and decrease mem-
ory as seen in several animal models for Zn deficiency (23). More importantly, 
key proteins involved in the etiology of AD, and especially early-onset AD 
(familial AD), such as amyloid precursor protein (APP), presenilin 1 (PS1), and 
presenilin 2 (PS2), have been shown to bind to or regulate  metals. For example, 
PS are important for cellular Cu and Zn turnover (24). Further, metals have 
been shown to interact with the two major disease-related proteins of AD, 
namely Aβ and  tau.
METAL INTERACTIONS WITH APP
The APP is expressed in various tissues of the human body, in particular in the 
 brain. Its general function within the brain has been linked to neurite outgrowth 
and neuronal cell migration (25). However, it becomes increasingly evident that 
APP can be considered to act as a metalloprotein, which is involved in the regula-
tion of Cu, Fe, and ferroxidase homeostasis (26). Recent studies indicate further-
more that metals are involved in the proteolytic processing of  APP.
APP displays two putative metal-binding sides, which are located within the 
E1 (124–189, APP770 numbering) and E2 (376–554) domains (27, 28). Cu 
binds to APP between residues 142 and 166 (29). It has been demonstrated that 
the two Cu-binding residues 149 and 151 are involved in the metabolism, folding 
and stability, and homodimerization of APP (30). Besides, Cu ions have been 
shown to promote cell surface localization of APP (31). Furthermore, it has been 
shown that cellular Cu levels can influence the expression of APP in vitro at both 
gene and protein levels (32).
APP also displays an evolutionary conserved Zn-binding site between amino 
acid positions 170 and 188 (33, 34). The binding of Zn to APP has been reported 
to play a similar role as Cu-binding in the homodimerization of APP (35) 
(Figure 2 A).
Fe is involved in the direct regulation of APP  translation. The APP mRNA dis-
plays an Fe response element (IRE) in its 5’-untranslated region (5’-UTR) sequence 
(36), and APP levels increase after a rise in cytosolic free Fe levels (37). Additionally, 
APP has been suggested to be involved in Fe export in the brain through the sta-
bilization of ferroportin  (Fpn). Deletion of APP in vitro in primary neurons impairs 
Fe export, which can be fully restored by the addition of APP (38).
Aβ is derived from APP by the sequential proteolysis by β- and  γ-secretases. 
Metals have also been shown to indirectly influence Aβ generation by modifying 
the proteolytic processing of APP (28). Interestingly, all three secretases 
(α, β, and γ) involved in the enzymatic cleavage of APP interact with metal  ions. 
The enzymatic activity of the α-secretase TACE is regulated by a “cysteine 
switch” motif, which is based on an intramolecular bond between cysteine (Cys) 
and a Zn atom in its catalytic site (39). Furthermore, the major β-secretase 
involved in APP processing displays a Cu-binding site in its C-terminal domain 
(40). Further, Zn has been shown to enhance the synthesis of PS1, the active 
subunit of the γ-secretase (41).
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METAL INTERACTIONS WITH AMYLOID-BETA (Aβ)
The Aβ domain of APP is another region that can directly bind Zn and Cu ions; 
however until now, there is no evidence that this region interacts with metal ions 
prior to the enzymatic cleavage mediated by α-, β-, and γ- secretases (42) 
(Figure 2 B).
Aggregation of Aβ into insoluble fibrils is a key pathological event in AD and 
is mediated by the interactions of Aβ with metals, in particular, Zn, Cu, and  Fe. 
Early studies have shown that in particular, the histidine (His) residues in Aβ 
are responsible for the metal-mediated aggregation of Aβ (43). Interestingly, in 
mice and rats, the same His residues are not present, which might explain why 
these animals are more resistant to the amyloid pathology compared to other 
mammals (44).
Figure 2 APP cleavage and APP and tau metal-binding sites. A) Cleavage of APP by α- and 
γ-secretases creates the sAPPα and Aβ17-40/42 fragments (upper panel). Cleavage by β- and 
γ-secretases creates the sAPPβ and Aβ1-40/42 fragments (lower panel). The N-terminal part of 
APP contains a CuBD, copper-binding domain; ZnBD, zinc-binding domain; HepBD, 
heparin-binding domain; GFD, growth factor-like domain. B) Two of several possibilities of 
metal interaction with Aβ. Below: Sequence of Aβ, 3 His in the Aβ peptide domain of human 
wild type (wt) Aβ are important for metal coordination. C) Representation of the three main 
domains studied in tau protein. The picture shows the binding sites of Cu and Fe, 
respectively, through R1, R2, and R3 regions in the MTB ensuring the binding to the 
microtubules.
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The strong chelation properties of Aβ of Zn, Cu, and Fe explain the enrich-
ment of these ions in amyloid plaques and suggest that one potential pathological 
influence of Aβ might be to sequester metal ions (45) and, through increasing 
concentrations of redox-active Cu and Fe ions in amyloid plaques, to promote 
oxidative  stress.
Zinc and Amyloid-Beta
Zn is a factor contributing to the neurotoxicity of Aβ through the stabiliza-
tion of amyloid fibrils (46). Various coordination sites have been proposed 
for the binding of zinc to Aβ with particular importance of His13 and His6. 
In vitro studies demonstrated that Zn induces the rapid and extensive aggre-
gation of synthetic Aβ (34, 47), which might act as a seeding factor in the 
formation of amyloid  plaques. In support of these studies, high levels of Zn 
have been found in the senile plaques of postmortem tissue of AD patients 
(45) and plaques of genetic AD mouse  models. Interestingly, Aβ deposits fail 
to develop into mature plaques in the cerebellum where vesicular Zn is 
 absent. Scavenging of Zn ions through Aβ may itself be a pathomechanism of 
 AD. A locally decreasing Zn level in the vicinity of plaques contributes to 
synapse loss (13).
Copper and Amyloid-Beta
Homeostasis is fundamental for all metal ions, but for Cu it is critical because this 
metal is redox-active and can catalyze and activate O2, generating reactive oxygen 
species (ROS) involved in oxidative  damage. The soluble monomeric Aβ displays 
three high-affinity His Cu-binding sites (His6, His13, and His14), which along 
with the N-terminal amino group and aspartate form a tetragonal complex with 
Cu ions (48, 49). Cu(II) has been demonstrated to play a crucial role in the forma-
tion of β-sheet structures, which are thought to be a preliminary step of the toxic 
aggregates of the fibrillar form of  Aβ. Thus, Cu binding to Aβ has been proposed 
to play a major role in the neurotoxicity of  Aβ. In line with this, a series of studies 
have reported that Cu chelators rapidly induce the inhibition of Aβ accumulation 
in transgenic AD mouse models (50, 51).
Other essential trace metals and Amyloid-Beta
Because of Fe3+ hydroxide species precipitation, the binding of Fe3+ to Aβ seems 
 implausible. Instead, Asp1, Glu3, and the three His residues (His6, His13, and 
His14) are involved in binding of Fe2 +. However, iron mineral deposits in the 
cortical tissue may occur in vivo and contain magnetite (Fe3O4). They have been 
found in tissue extracted from human AD brain and brain from APP/PS1 trans-
genic mice (52). The aggregation state of Aβ appears to affect iron redox cycle and 
consequently may lead to the release of free radicals via Fenton  chemistry. 
Interestingly, the degree of altered iron accumulations in AD is correlated with the 
amount of Aβ plaque  pathology. However, these changes appear to occur after the 
development of the AD pathological hallmarks (53). Increased aggregation of 
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Aβ has been observed through the down-regulation of the enzymes that regulate 
the degradation of extracellular Aβ deposits induced by high Mn levels (54).
Toxic trace metals and Amyloid-Beta
Several studies have suggested that Al interacts with  Aβ. Al has been detected in 
both the Aβ plaques and  NFTs. Treatment of neuronal cultures with Al resulted in 
a marked accumulation of Aβ aggregates in  vitro. However, the relevance of this 
for AD pathology in vivo is currently not well understood (48). Similarly, Hg 
exposure has been shown to promote the accumulation of Aβ deposits in  vitro. 
Cd, like Mn, has been reported to reduce the expression of Aβ-degrading enzymes, 
resulting in an increased Aβ accumulation(48).
METAL INTERACTIONS WITH TAU
In AD, Tau aggregates due to hyperphosphorylation, abnormal splicing, or muta-
tion in the tau encoding gene (55, 56). AD is the most common tauopathy among 
degenerative brain  diseases. The tauprotein, with a molecular weight between 
50 and 68 kDa, is encoded by a single gene (MAPT) located on chromosome 
17q21 in  humans. Tau is mainly localized in neuronal axons, but also dendrites 
(57), in the central nervous system  (CNS). Tau is a microtubule-associated pro-
tein (MAP) implicated in the stabilization and integrity of microtubules (MT) in 
neurons, and its activity is regulated through a phosphorylation-dependent 
mechanism (58). In physiological conditions, tau is phosphorylated (facilitating 
the disassociation of the protein from the MT) and dephosphorylated (promoting 
the binding with MT) through the activity of tau kinases and phosphatases (59). 
In the human brain, under developmental control, six different isoforms of tau 
exist with a variation in size from 352 to 441 amino  acids. The isoforms differ in 
the inclusion or exclusion of N repeats (0N or 1N or 2N) at the amino-terminal 
region and for the presence of three (3R) or four (4R) MT-binding domain (MTB) 
repeats (R) in the carboxyl-terminal part of the molecule (60).
The major domains identified in the tau protein are the projection domain, situ-
ated in the acidic N-terminal part, and the assembly domain, localized in the basic 
C-terminal  domain. The two domains with the opposite charge are separated from 
one another by the proline (Pro)-rich region, situated in the middle part of the 
 protein. Here, tau interacts with proteins containing an SH3  domain. Further, the 
Pro-rich region is the target of different Pro-directed kinases and also FYN-tyrosine 
kinases (61). The assembly domain, through R1–R4 repeat regions and flanking 
domain, binds microtubules and supports their  assembly. This domain is the key 
in the regulation of the phosphorylation state of the tau protein (62). On the con-
trary, the projection part does not interact with microtubules but projects away 
from their surface interacting with other cytoskeletal elements, mitochondria or 
the neuronal plasma membrane (63, 64).
Phosphorylation of tau plays a crucial role in the pathogenesis of AD (65, 66) 
introducing negative charge(s) that promote an electrostatic interaction with metal 
ions (67) (Figure 2 C). Tau abnormal phosphorylation leads to an abnormal struc-
ture, that is, polymerized into paired helical filaments (PHFs) which may further 
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aggregate to form NFTs, assuming the shape of a toxic protein deprived of the 
biological functions typical of the MAP  family. It was reported that in AD brains, 
NFTs include metals, confirming an association between endogenous redox-active 
transition metals and metal-binding sites in tau (68). Binding of a series of metal 
ions including the essential biometals, Zn, Cu, Fe, Mg, and Mn, and non-essential 
trace metals, Pb, Cd, Hg, and Al, may promote tau hyperphosphorylation and 
induce tau  aggregation. In contrast, Fe and lithium (Li) reduce the abnormal 
phosphorylation of tau (48). For this reason, biometal homeostasis is essential, 
and the disruption of this balance may play a key role in the pathogenesis of  AD.
Zinc and Tau
A disruption in the Zn homeostasis leads to a series of pathogenic conditions in 
the AD brain, including the formation of NFTs composed of hyperphosphorylated 
 tau. Recent studies show that Zn is involved in the mechanism of tau hyperphos-
phorylation via two different interactions: in vitro, Zn can directly affect tau at 
serine (Ser) and Pro sites, at threonine (Thr) and Pro sites or via two Cys residues: 
C291 and C322 (69). At the same time, Zn can indirectly hyperphosphorylate tau 
protein, by activating kinase and phosphatase pathways, for example activating 
Raf/mitogen protein kinase and inhibiting phosphatases such as PP2A (70, 71).
These two independent ways of action have different effects on tau  toxicity. 
It has been demonstrated that the direct interaction between tau and Zn plays an 
important role in tau toxicity: after removing the Zn-binding site, tau toxicity is 
completely abolished, assuming that the toxic effect of tau necessitates both the 
presence of hyperphosphorylation and Zn  bond. Tau hyperphosphorylation path-
ways appear to be less toxic, compared to tau toxicity that occurs from the direct 
binding between tau and Zn (72). Recently, it has been discovered that Zn could 
be considered a catalyst, accelerating the aggregation of tau-R3 complexes and, at 
the same time, promoting the formation of tau oligomers (73, 74). Thus, correct 
Zn homeostasis in AD is fundamental because abnormally high concentrations of 
this mineral induce the development of granular tau aggregates, while abnormally 
low concentrations of Zn lead to amyloid fibril formation (75).
Copper and Tau
A high concentration of Cu (0.4 mM) was reported in amyloid plaques and  NFTs. 
Thereby, NFT may be linked to high levels of redox-active Cu (68). Besides, Cu is 
involved in tau hyperphosphorylation by activating the cyclin-dependent kinase 
(CDK)5/p25  complex. Tau hyperphosphorylation resulting from the activation of 
GSK-3β kinase by Cu is controversial: some studies suggest that GSK-3β kinase is 
activated by Cu (76, 77), while other studies propose that GSK-3β kinase may not 
necessarily be involved in the abnormal phosphorylation of the protein (78). The 
binding between tau and Cu is highly  selective. Studies revealed that the full-
length Human Tau40 isoform (K32) can bind one Cu for each monomer (1:1 
binding stoichiometry) with a dissociation constant (Kd) close to 1 µM via two Cys 
 residues. The sequences mediating the binding of Cu are 287VQSKCGS293 and 
310YKPVDLSKVTSKCGS324. An analysis conducted by circular dichroism and 
nuclear magnetic resonance (NMR) spectroscopy showed only limited formation 
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of aggregates after binding Cu because the addition of Cu to K32 does not affect 
the secondary structure, and thus, tau remains mostly disordered (79). In vitro, it 
has been demonstrated that Cu can bind different tau fragments containing 
diverse MTBR such as R1 and R2, showing alterations in the secondary structure 
(80, 81). Furthermore, the interactions between tau R2 and Cu lead to the pro-
duction of H2O2 (82). The repeat R3 can be associated with more than one Cu ion 
via two His residues (83).
The role of Cu-binding to tau remains controversial, although some studies 
suggest that the binding between Cu and tau inhibits the formation of abnormal 
aggregates in vitro (78, 81). For example, increasing intracellular Cu levels by the 
addition of Cu–bis (thiosemicarbazone) complexes, inhibits tau hyperphosphory-
lation (76).
Iron and Tau
Fe dysregulation is linked to oxidative stress in  tauopathies. Fe, as Zn and Cu, 
interacts with some of the isoforms of the tau protein, causing irreversible struc-
tural  changes. The result of this interaction is protein aggregation and/or oxidative 
stress, through the Fenton reaction, perpetuating a condition of cellular  damage. 
Analysis of postmortem AD brains shows increased Fe levels in several brain 
regions (84).
In the human body, Fe is available in two oxidation states: Fe3+ (redox-inert 
state) that is stored in ferritin and Fe2+  (redox-active). The iron status associated 
with NFTs in AD is Fe3+, which can induce the aggregation of hyperphosphory-
lated  tau. Fe-binding sites using His residues have been identified in tau (85). The 
hyperphosphorylated status of tau may not involve Fe3+ interacting with the pro-
tein, but Thr phosphorylation can regulate the interaction between tau and 
Fe2+ (86). Thus, the phosphorylation level of tau causes conformational changes 
of tau to mediate tau–Fe interactions (87). In addition to a direct interaction, Fe 
induces tau hyperphosphorylation, both in vitro and in vivo, by activating the 
CDK5/p25 complex and GSK-3β and MAP kinases (88). This evidence suggests a 
possible role of iron involved as a co-factor for tau  aggregation.
Other essential trace metals and Tau
In AD patients, Mg levels appear lower (540–625 µg/g) compared to the physio-
logic range (620–680 µg/g) (89). In vivo, data obtained from an AD transgenic 
mouse model show that Mg increases the phosphorylation of the GSK-3β kinase 
at Ser9, which in turn reduces the hyperphosphorylation of tau protein (90). 
Additionally, in postmortem brains of patients affected by AD, the level of Mn 
appears to be higher (91). An increase of Mn levels is related to abnormal tau 
aggregation and its hyperphosphorylation, mediated by GSK-3β kinase (92).
Toxic trace metals and Tau
Al is the most widely exogenous metal ion distributed in the  environment. As 
Fe3+, Al3+ is a trivalent cation that influences protein phosphorylation of tau 
(93, 94). Recent data show that Al can promote the formation of sodium dodecyl 
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sulfate (SDS)–resistant tau oligomers after tau phosphorylation (95). The role of 
Al in AD has been intensively investigated since NFT-like deposits were discov-
ered in mammalian brains after intracerebral Al injection (96). Al has been shown 
promoting tau aggregation through the down-regulation of PP2A activity and an 
increase of CDK5 and GSK-3β kinase levels (97). Thus, Al, although not directly 
binding to tau, may have a role as co-factor in AD (98).
Further, heavy metals such as Cd, Pb, and Hg have been implicated in AD 
pathology (99). Data show that Cd is involved in the formation of NFTs (100, 
101). Both in cell models and in in vivo studies, Cd increases the activation of 
GSK-3β kinase, causing the hyperphosphorylation of tau (102). Similarly, Pb has 
been reported to modulate tau aggregation by increasing the activity of CDK5/p25 
complex and GSK-3β kinase (103). Hg was demonstrated to inhibit tubulin that 
has a very high-affinity binding-site for Hg (104). Once Hg binds tubulin, the 
structural integrity of the protein is  impaired. The final result of this interaction 
between Hg and tubulin is the formation of NFTs (105). Also, Hg is involved in 
tau hyperphosphorylation; the mechanism starts with the oxidative stress induced 
by Hg, ultimately affecting tau phosphorylation status (106).
OTHER METAL-BINDING PROTEINS AND THEIR ROLE IN AD
Several of the effects of an altered trace metal status in AD such as increased oxida-
tive stress, neuroinflammation, and effects on synapses are mediated by excess or 
lack of trace metals for binding to proteins other than Aβ and  tau. Together with 
several other factors in AD, oxidative stress leads to an activation of the immune 
 system. The immune system is highly dependent on trace metal  biology. Especially, 
Zn signaling seems to be a key mediator of inflammatory  responses. For example, 
the activity of NF-κB (nuclear factor kappa-light-chain-enhancer of activated 
B cells), a major regulator of pro-inflammatory cytokines such as interleukins (IL) 
(107), is regulated, among others, by Zn through Zn binding of the IKK (IκB 
kinase) complex member IKKβ (108). Further, the formation of senile plaques 
made of Aβ aggregates stimulates inflammasomes, such as the NLRP3 (nucleo-
tide-binding domain and leucine-rich repeat-containing family, pyrin domain-
containing-3) inflammasome that detects the inflammatory Aβ aggregates and 
responds by forming active IL-1β through secreting caspase-1 (Casp-1) (109). 
IL-1β acts as an inflammatory cytokine (110), which leads to the creation of an 
inflammatory environment around the  plaque. This ultimately decreases plaque 
degradation and destruction by microglia  cells. Zn deficiency and/or high Cu lev-
els facilitate NLRP3 inflammasome activation (111) and thereby the production of 
IL-1β in macrophages (112).
Initially, Pro-IL-1β is expressed in response to damage-associated molecular 
patterns (DAMPs) that bind to pattern recognition receptors (PRRs) on the mac-
rophage to upregulate pro-inflammatory gene  expression. Inflammation, protein 
misfolding, and aggregation, as well as neurodegeneration, lead to increased levels 
of so-called alarmins or DAMPs that include several cytokines including those 
from the S100  family. The S100 proteins are engaged in classical calcium- activated 
signaling but recent work has shown their involvement in new biochemical mech-
anisms in the brain related to the prevention of protein aggregation (113) and 
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sensing of neuronal Ca and Zn levels (114). Therefore, S100 alarmins are impli-
cated in the maintenance of protein homeostasis (proteostasis) and metal ion 
homeostasis (metallostasis) in the  brain. Upon activation and at high (μM) con-
centrations, S100 proteins act as extracellular cytokines via RAGE (receptor for 
advanced glycation end-products) mediated  signaling. RAGE persistent engage-
ment increases S100 extracellular levels via NF-κB activation resulting in a posi-
tive feedback cycle (115). Glial S100B and S100A9 proteins show increased 
expression in response to several risk factors for AD, including aging (116). 
Interestingly, S100B undergoes metal-binding-induced conformational changes 
and thereby delays the onset of Aβ aggregation by interacting with Aβ1–42 mono-
mers inhibiting primary nucleation (113). However, high levels of S100B can 
elicit alterations in intracellular Zn concentrations (114).
The increase in S100B proteins and accumulation of Aβ as a factor for trace 
metal imbalances also has direct effects on Zn signaling at excitatory glutamatergic 
 synapses. It has been shown that the dynamics of major postsynaptic scaffold 
proteins of these synapses (SHANK2 and SHANK3) are dependent on Zn avail-
ability (117). Studies have shown that SHANK platform disassembly is linked to 
the molecular pathology of AD (118, 119), and recent research confirmed that the 
progressive accumulation of Aβ results in decreased Zn concentrations at the syn-
apse, which in turn leads to disruption of SHANK3 scaffold formation, and ulti-
mately, loss of synapses (13). Thus, Zn sequestration by protein aggregates in AD 
may be a contributor to the cognitive impairments caused by the loss of synapses 
through trapping synaptic Zn rather than through neurodegeneration in general 
(120). In addition, NMDA receptors at synapses are Zn-binding proteins (121). 
Increased trapping of Zn lowers the inhibitory activity of Zn on the  NMDAR. 
Excessive stimulation of receptors at the excitatory synapse has been linked to 
neuronal death through excitotoxicity leading to chronic neurodegeneration in 
AD (122). Together, these metal-imbalance-driven signaling pathways create a 
vicious cycle leading to increased inflammation, oxidative stress, and neuronal 
damage (Figure 3).
METAL DETECTION FOR AD DIAGNOSIS
Several metal bioimaging strategies have been developed not only to examine the 
distribution of metals in human clinical AD brain tissue and AD mouse models 
but also to diagnose and monitor the progression of AD (123). In the clinical set-
ting, the most common imaging tool is magnetic resonance imaging  (MRI). This 
technique focuses on Fe due to its magnetic properties and its abundance in the 
 brain. The latest MRI technology provides sufficient resolution to detect regional 
differences and has the major advantage that it can be applied to living patients 
rather than being a tool for postmortem analysis only (124). The presence of 
localized Fe can be detected by MRI (T2). However, although detecting general 
metal dyshomeostasis, MRI has limitations in visualizing metal-loaded plaques 
directly with high  resolution. Further development of metal-based compounds or 
compounds visualizing metal homeostasis, such as a Cu-64-labelled–bis (thios-
emicarbazonato) complex for clinical application in positron emission tomogra-
phy (PET), and improvement of imaging devices may lead to more precise 
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Figure 3 Interaction between Aβ plaques, glial cells and trace metals. Senile plaques sequester 
large amounts of Zn, Cu, and Fe, creating a zone of metal depletion, especially Zn depletion, 
in their vicinity. While high levels of Cu and Fe at the center of plaques may contribute to the 
generation of ROS and damage neurons through oxidative stress, Zn deficiency in a zone 
surrounding plaques will lead to further effects: Accumulation of Aβ aggregates leads to the 
release of S100B from astrocytes. S100B as DAMP can initially prevent Aβ aggregation. 
However, S100B signals back to astrocytes via RAGE receptor activation that will, in turn, 
activate NF-κB. Active NF-κB is dis-inhibited by low levels of Zn and thus results in further 
production of S100B, which enters a positive feedback cycle. High levels of S100B further 
deplete Zn through Zn binding. In response to high DAMP levels (S100B), microglia cells will 
produce pro-IL-1β. This will be cleaved by Casp-1-dependent processes through the NLRP3 
inflammasome. NLRP3 activity is further increased by low Zn levels. Production of IL-1β leads 
to further generation of ROS and release of cytokines and chemokines from microglia cells 
that facilitate NFT formation and neurodegeneration. Further, low Zn levels facilitate 
excitotoxicity through dis-inhibition of NMDAR signaling, and low levels of Zn destabilize 
the postsynaptic Shank3 scaffold resulting in synapse loss.
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diagnosis and monitoring of progression and therapeutic effects based on the role 
of trace metals in AD in the future (124).
METALS HOMEOSTASIS AS A THERAPEUTIC 
STRATEGY FOR AD
Based on the interactions of metals with several key proteins of the AD pathology, 
different therapeutic approaches aimed at restoring or manipulating metal homeo-
stasis and, thereby, regulating oxidative stress, tau phosphorylation, Aβ aggrega-
tion, and inflammation have been developed in the last  decade.
For example, metallothionein 3 (MT-3), a key regulator of metal homeosta-
sis in neural tissue, has been found down-regulated by up to 30% in AD  brains. 
Given that MT-3 contributes, among others, to detoxification and storage of 
heavy metals, regulation of Cu and Zn metabolism, and modulation of Aβ 
endocytosis of astrocytes (125), increasing MT-3 levels in AD has been explored 
as therapeutic  strategy. In vivo studies demonstrated that effects of Zn-loaded 
MT-3 treatment in a mouse model for AD (Tg2576 mice) are inconsistent if 
MT-3 is injected  subcutaneously. However, MT-3 injected intracerebroventricu-
larly is able to ameliorate behavioral deficits and hippocampal impairments in 
APP/PS1  mice. In these mice, MT-3 treatment was also able to restore metal 
homeostasis, inhibit Aβ aggregation, and reduce oxidative stress and neurode-
generation (125).
Another interesting treatment strategy is based on metal protein attenuating 
compounds (MPACs): Clioquinol (CQ) represents the prototypic  MPAC. It is a 
small hydrophobic molecule that can cross the BBB and that has moderate affinity 
for metal  ions. When administered to Tg2576 mice, a 49% decrease of Aβ in the 
brain of AD model mice compared to control mice was shown (126). In humans, 
oral CQ treatment for 36 weeks of severely affected AD patients was able to sig-
nificantly prevent cognitive  deterioration. Subsequent clinical studies of this com-
pound were not  pursued. However, PBT2, a highly soluble derivate of CQ 
(a second-generation MPAC), has been used first in APP/PS1 mice and then in 
human clinical trials (phase I and  II). The results showed improved cognitive 
performance and reduced Aβ load in the mouse  model. A 12-week-long treatment 
of 78 patients with early AD showed that PBT2 is safe (127). Although the effects 
of PBT2 were inconsistent, executive dysfunction was significantly reduced in the 
 patients. Several other metal chelators were engineered over the last years, and 
most of them are currently investigated for use in  AD. Some of them have been 
shown to be effective at inhibiting Aβ–metal interactions both in vitro and in  vivo. 
For example, it has been demonstrated that the normally insoluble Aβ deposits of 
postmortem brain tissue from AD patients can be solubilized in aqueous media in 
the presence of specific Cu chelators (128).
Another promising approach is the delivery of metals directly to the brain 
using nanotechnological  approaches. Polymeric g7-poly-lactide-co-glycolide 
(PLGA) nanoparticles (NPs) are able to cross the BBB and release metals within 
the  brain. This system has been considered as a Trojan horse strategy to effectively 
deliver Zn to the brain with a low-toxicity profile (129). Three hours after ip injec-
tion of NPs, an increase of Zn levels in the brain and the increase of zinc-sensitive 
Metals in Alzheimer’s Disease 99
genes such as MT and Zn transporters were seen (130). The same pharmacologi-
cal approach applied to APP23 mice, an animal model of AD, showed promising 
effects such as Aβ dis-aggregation, a reduction of inflammation, and synapse sta-
bilization (129). Thus, both redistribution of metals bound to Aβ through MPACs 
and increase in metal levels that has dropped through trapping of metals in Aβ 
deposits have beneficial  effects. However, additional research is necessary to rede-
fine time point of application, duration, and concentration of NP-based metal 
 delivery.
CONCLUSIONS AND FUTURE PERSPECTIVES
In general, impaired biometal homeostasis and/or the accumulation of non- 
essential trace metals have significant effects, most prominently on proteotoxic 
stress, synapse function, oxidative stress, and inflammatory  processes. Building 
on the metal-binding abilities of key proteins in AD, brain imaging-based meth-
ods for the diagnosis of AD in humans have been, and are, currently  developed. 
However, despite improving techniques for the detection of trace metals in the 
brain, re-establishing metal balances remains a difficult  task. Initial studies using 
Zn ionophores have been promising and showed that targeting metal homeostasis 
in AD may be one of the most auspicious therapeutic  strategies. However, new 
targeted and improved approaches are needed in the  future.
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